Sign in
ZVSA Stock Price, Chart, Stats & News
ZyVersa Therapeutics, Inc.
Save
ZyVersa Therapeutics, Inc. (ZVSA) does not currently pay a dividend.
–
Market cap
–
Current P/E
–
Forward P/E
ZVSA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 50.00% |
Operating margin | -16075212.16% |
Pretax margin | -17218839.17% |
Net margin | -98533.27% |
Effective tax rate | 0.02% |
ROA | -2470.10% |
ROE | -932.60% |
D/E | – |
Interest coverage ratio | -8077.14x |
ZVSA valuation
P/E | – |
P/S | 60.23x |
P/B | -1.28x |
P/CF | -0.00x |
P/FCF | -0.00x |
P/OCF | -0.00x |
PEG | 0.22x |
EV multiple | -0.08x |
About
ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease. Furthermore, ZyVersa is advancing IC 100, a pioneering inflammasome ASC inhibitor positioned to tackle a wide array of inflammatory conditions.
Similar securities
Based on sector and market capitalization
Report issue